(MENAFNEditorial) CAMBRIDGE, Mass., March 20, 2018 /PRNewswire/ --Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today that it is not proceeding with its proposed public offering of 9,000,000 shares of its common stock in an underwritten public offering previously announced on March 19, 2018. The company believes that current market conditions are not conducive for an offering on terms that would be in the best interest of its current stockholders.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing. Headquartered in Cambridge, MA, the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. In addition to its multiple programs in cystic fibrosis, Proteostasis Therapeutics has formed a collaboration with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions as well as risks and uncertainties inherent in Proteostasis' business, including those described in the company's periodic filings with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facingProteostasiscan be found under the heading "Risk Factors" inthe Company'speriodic reports, including its annual report on Form 10-K for the year ended December 31, 2017 available on theSEC'sweb site at www.sec.gov . Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACTS:
Investors:
David Pitts
Argot Partners
212.600.1902
Media:
David Rosen
Argot Partners
212.600.1902
View original content with multimedia: http://www.prnewswire.com/news-releases/proteostasis-therapeutics-announces-withdrawal-of-equity-offering-due-to-market-conditions-300617202.html
SOURCE Proteostasis Therapeutics, Inc.
MENAFN2003201800701241ID1096627092
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.